MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside

Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. The different systemic treatment approaches attempted in the last 35 years have not improved overall survival in the advanced stage. Targeted therapies assessed in clinical trials have failed to show efficacy against SCLC. Wit...

Full description

Bibliographic Details
Main Authors: Max Hardy-Werbin, Raúl del Rey-Vergara, Miguel Alejandro Galindo-Campos, Laura Moliner, Edurne Arriola
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Cancers
Subjects:
small cell lung cancer
MET
HGF
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/11/10/1404

Similar Items

Similar Items